In biomedical research and biomanufacturing, the purity of reagents directly impacts the reliability of experimental outcomes and the safety of downstream therapeutic products. Endotoxins are notorious contaminants in protein preparations. Even trace amounts of endotoxin in recombinant proteins can trigger potent immune responses, distort results, and compromise patient safety, especially in sensitive applications such as immunology, cell and gene therapy, and vaccine production. Sino Biological has addressed this urgent need with the launch of ProPure™, an advanced line of endotoxin-free recombinant proteins.
New CEO takes over
AppointmentsContract Research Organization Julius Clinical (NL) appointed Bassem Saleh as its new Chief Executive Officer. His predecessor, Martijn Wallert, will become an advisor to the Executive Board.
Euphoria in Milan: Italian Nanophoria closes €83m financing round in heart failure
Latest NewsItalian NanoPhoria Bioscience raises surprisingly high €83.5 million to advance novel heart failure therapy with a very early non clinical asset.
British Owlstone Medical wins ARPA-H award, but will it materialize?
Latest NewsOwlstone Medical, a pioneer in breath-based diagnostics from Cambridge (UK), has been awarded up to US$49.1m by the U.S. health innovation agency ARPA-H under its POSEIDON programme. The funding backs development of a synthetic-sensor MCED test capable of detecting over 30 solid tumours at Stage I using breath and urine samples, intended for at-home, over-the-counter use. But will ARPA-H be committed to funding if the restructuring of NIH and HHS in the US is moving in a different direction?
Roche gets CE mark for chronic kidney disease algorithm
Latest NewsRoche Diagnostics and its partner KlinRisk Inc have received the EU CE mark for the very first AI-based risk stratification tool that reliably assesses progressive decline in kidney function.
FDA approves atezolizumab–lurbinectedin for ES-SCLC
Latest NewsThe U.S. FDA has approved atezolizumab and atezolizumab with hyaluronidase in combination with lurbinectedin as the first and only first-line maintenance therapy for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after induction therapy with atezolizumab, carboplatin and etoposide.
New Chief Scientific Officer has started
AppointmentsTessellate Bio (Naarden, Netherlands; Stevenage, UK) appointed Dr Katie Chapman as Chief Scientific Officer (CSO) at the end of September. She succeeds Dr Jürgen Moll, who will be available to the company in an advisory capacity.
Pharma Tariffs: US Government backtracks
Latest NewsAfter the surprising announcement of a 100% tariff on all prescription drugs imported into the United States, the US government appears to be backtracking. Within a few days, its trade policy stance towards the pharmaceutical industry has shifted fundamentally.
Biologics CDMO Rezon Bio leaves stealth mode
Latest NewsRezon Bio has launched as a European contract development and manufacturing organisation (CDMO) for biologics. The new company has been created following the demerger of Polpharma Biologics into two independent companies.
ProPure™: Raising the Bar in Life Science Research
slider, Sponsored PublicationsIn biomedical research and biomanufacturing, the purity of reagents directly impacts the reliability of experimental outcomes and the safety of downstream therapeutic products. Endotoxins are notorious contaminants in protein preparations. Even trace amounts of endotoxin in recombinant proteins can trigger potent immune responses, distort results, and compromise patient safety, especially in sensitive applications such as immunology, cell and gene therapy, and vaccine production. Sino Biological has addressed this urgent need with the launch of ProPure™, an advanced line of endotoxin-free recombinant proteins.
Genmab swallows Merus in US$8bn deal
Latest NewsDanish Genmab A/S has acquired the Dutch oncology specialist Merus NV for US$8bn in cash. The 41% premium over Merus’s share price at Friday is largely attributed to the bispecific EGFR x LGR5 antibody, Petosemtamab